Nature Reviews Drug Discovery

CN Bio and Altis Biosystems Partner to Develop Next-generation Human Gut/Liver in vitro model for Advanced ADME Studies

Retrieved on: 
Tuesday, January 23, 2024
Health, Health Technology, Other Science, Research, Science, Pharmaceutical, Biotechnology, Pharmacy, Animal, Partnership, Nature Reviews Drug Discovery, MPS, Olympia, Greece, ADME, Absorption, Drug discovery, Drug development, System, Metabolism, Pharmacokinetics, Pharmaceutical industry

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Key Points: 
  • CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
  • CN Bio and Altis’ integrated Gut/Liver MPS bridges this gap for more accurate predictions of human drug oral bioavailability earlier in the drug development process.
  • Primary human cells are considered the gold standard for advanced in vitro models; however, gut cells present challenges that limit their use.
  • By interconnecting the RepliGut Planar-Jejunum model with CN Bio’s industry-leading primary human Liver-on-a-Chip, the dual-organ Gut/Liver model represents the next-generation of CN Bio’s oral bioavailability assay.

How Might Biomolecular Condensates Revolutionize Drug Discovery? A Perspective from Dewpoint Therapeutics

Retrieved on: 
Wednesday, August 17, 2022
Condensate, Multimedia, Drug discovery, Cancer, Cardiomyopathy, Coronavirus Scientific Advisory Board (Turkey), Nature Reviews Drug Discovery, Hope, Epistasis, Patient, Therapy, Degenerative disease, Dew point, Biology, Neurodegeneration, Logic, Disease, Pharmaceutical industry, Medical device

BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.

Key Points: 
  • BOSTON, Aug. 17, 2022 /PRNewswire/ -- A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.
  • In "Modulating biomolecular condensates: a novel approach to drug discovery," a Dewpoint Therapeutics perspective, the authors discuss the largely untapped opportunities for targeting biomolecular condensates to develop therapeutic agents for various diseases.
  • Condensate-targeted drug discovery was pioneered by Dewpoint Therapeutics as the firstbiotech company to enter the field, founded in 2018.
  • Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.

Clarivate Names World's Leading Journals with the 2022 Journal Citation Reports

Retrieved on: 
Tuesday, June 28, 2022
Factor X, Academy, The New England Journal of Medicine, Critical care, Nature Reviews Molecular Cell Biology, SSCI, Publication, Journal, Invention, Research, JCR, Technology, Clarivate, SCIE, Bya, Health and wellbeing board, Book, COVID-19, Internal medicine, Blog, Drug discovery, Sustainable development, Journal Citation Reports, Health care, Final good, Public health, UN, Policy, Infection, Literature, JIF, Journal of General Internal Medicine, List of life sciences, NYSE, Librarian, Editorial, JAMA, The Lancet, Nature Reviews Drug Discovery, Solution, Jif, Vaccine, Professional services, Impact factor, Twitter, American Medical Association, Collection, Pharmaceutical industry, Medical device, Periodical literature, Health, Lancet

LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR)™. The annual JCR release enables the research community to evaluate the world's high-quality academic journals using a range of indicators, descriptive data and visualizations. The reports are used extensively by academic publishers across the globe to understand the scholarly impact of their journals relative to their field and promote them to the research community. 

Key Points: 
  • LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR) .
  • Clarivate monitors and excludes journals that demonstrate anomalous citation behavior including where there is evidence of excessive journal self-citation and/or citation stacking.
  • Key facts from the 2021 data:
    The Journal Citation Reports contains more than 21,000 journals, from 254 research categories and 114 countries.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.

Clarivate Names World's Leading Journals with the 2022 Journal Citation Reports

Retrieved on: 
Tuesday, June 28, 2022
Factor X, Academy, The New England Journal of Medicine, Critical care, Nature Reviews Molecular Cell Biology, SSCI, Publication, Journal, Invention, Research, JCR, Technology, Clarivate, SCIE, Bya, Health and wellbeing board, Book, COVID-19, Internal medicine, Blog, Drug discovery, Sustainable development, Journal Citation Reports, Health care, Final good, Public health, UN, Policy, Infection, Literature, JIF, Journal of General Internal Medicine, List of life sciences, NYSE, Librarian, Editorial, JAMA, The Lancet, Nature Reviews Drug Discovery, Solution, Jif, Vaccine, Professional services, Impact factor, Twitter, American Medical Association, Collection, Pharmaceutical industry, Medical device, Periodical literature, Health, Lancet

LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR)™. The annual JCR release enables the research community to evaluate the world's high-quality academic journals using a range of indicators, descriptive data and visualizations. The reports are used extensively by academic publishers across the globe to understand the scholarly impact of their journals relative to their field and promote them to the research community. 

Key Points: 
  • LONDON, June 28, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released the 2022 update to its annual Journal Citation Reports (JCR) .
  • Clarivate monitors and excludes journals that demonstrate anomalous citation behavior including where there is evidence of excessive journal self-citation and/or citation stacking.
  • Key facts from the 2021 data:
    The Journal Citation Reports contains more than 21,000 journals, from 254 research categories and 114 countries.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Retrieved on: 
Friday, May 13, 2022
Diabetes, JAMA, Nature Reviews Drug Discovery, Company, Glucose, National Medical Products Administration, BMJ, Blood, Journal, Drug discovery, American Diabetes Association, GSIS, Pancreas, Medical college, Patient, Hypoglycemia, Homeostasis, Phase, NEJM, DAWN, Liver, Medical journal, Nanjing University, GKA, The New England Journal of Medicine, Trial of the century, Research, FPG, ADA, GK, NMPA, Safety, Insulin, Glucagon, NDA, American Medical Association, The Lancet, Metformin, Glucokinase, Insulin resistance, SEED, Medical Center, Hong Kong Stock Exchange, Inborn errors of metabolism, Glycated hemoglobin, Nature Medicine, Pharmaceutical industry, Medical device, Endocrinology, T2D, Lancet

The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.

Key Points: 
  • The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.
  • Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology.
  • These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.

CD&R Announces Anand Shah, M.D., Former FDA Deputy Commissioner, as Operating Advisor

Retrieved on: 
Thursday, February 3, 2022
Associate Director of National Intelligence and Chief Information Officer, Duke University School of Medicine, Patient, UDG Healthcare, Therapy, CMS, Public health, Food, Food and Drug Administration, Publication, Clayton, Dubilier & Rice, University, Policy, Center, CD&R, National, The New England Journal of Medicine, Nature Reviews Drug Discovery, Drug discovery, R, Columbia University, JAMA, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Centers for Medicare & Medicaid Services, Health policy, Efficiency, Medicare, COVID-19, Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Company, Dubilier, Leonard Davis Institute of Health Economics, Duke University, Investment, Advanced manufacturing, FDA, Health, Federation, Multimedia, CD, Economics, Hero, Pharmaceutical industry, Cancer

NEW YORK, Feb. 3, 2022 /PRNewswire/ --Clayton, Dubilier & Rice today announced Anand Shah, M.D., former U.S. Food and Drug Administration ("FDA") Deputy Commissioner for Medical and Scientific Affairs, as an Operating Advisor to CD&R funds.

Key Points: 
  • NEW YORK, Feb. 3, 2022 /PRNewswire/ --Clayton, Dubilier & Rice today announced Anand Shah, M.D., former U.S. Food and Drug Administration ("FDA") Deputy Commissioner for Medical and Scientific Affairs, as an Operating Advisor to CD&R funds.
  • Dr. Shah will work with CD&R's healthcare team to source new investments and advise the funds' healthcare businesses.
  • At the FDA, he led consensus policy development for fit-for-purpose programs, including Advanced Manufacturing, vaccine development, digital health, consumer protection, and decentralized clinical trials.
  • During the COVID-19 pandemic, Dr. Shah guided the FDA's policy development for preparedness and recovery efforts.